BELLUS Health (TSE:BLU) Hits New 1-Year High at $10.26

BELLUS Health Inc (TSE:BLU)’s share price hit a new 52-week high during trading on Monday . The company traded as high as C$10.26 and last traded at C$10.06, with a volume of 53733 shares changing hands. The stock had previously closed at C$2.77.

Separately, Bloom Burton reaffirmed a “buy” rating on shares of BELLUS Health in a report on Thursday, August 1st.

The company has a debt-to-equity ratio of 0.56, a current ratio of 6.11 and a quick ratio of 6.04. The stock has a market cap of $438.45 million and a price-to-earnings ratio of -79.47. The firm has a fifty day moving average of C$3.11 and a 200 day moving average of C$1.92.

In related news, Director Franklin Milan Berger purchased 50,000 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The stock was purchased at an average price of C$2.70 per share, with a total value of C$134,925.00. Following the completion of the acquisition, the director now owns 1,502,108 shares in the company, valued at C$4,053,438.44.

BELLUS Health Company Profile (TSE:BLU)

BELLUS Health Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease.

Read More: Initial Public Offering (IPO)

Receive News & Ratings for BELLUS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BELLUS Health and related companies with MarketBeat.com's FREE daily email newsletter.